Pivotal bioequivalence trial of Ztilido vs Lidoderm in volunteers.

Trial Profile

Pivotal bioequivalence trial of Ztilido vs Lidoderm in volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Dec 2016

At a glance

  • Drugs Lidocaine (Primary)
  • Indications Postherpetic neuralgia
  • Focus Pharmacokinetics; Registrational
  • Sponsors Scilex Pharmaceuticals
  • Most Recent Events

    • 05 Dec 2016 According to Sorrento Therapeutics media release, the full data will be resubmitted to the U.S. Food and Drug Administration (FDA) as part of the new drug application (NDA) in mid-2017.
    • 05 Dec 2016 Results published in the Sorrento Therapeutics Media Release.
    • 05 Dec 2016 Primary endpoint has been met, according to Sorrento Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top